Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 39717004.
- Also identified by DOI 10.14309/ajg.0000000000003208.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood. Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response. Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year ( P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores. GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.
Medical subject headings
- Glucagon-Like Peptide-1 Receptor Agonists
- Glucagon-Like Peptides
- Inflammatory Bowel Diseases